News & Resources

Overview

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB32 (naltrexone sustained release (SR) / bupropion SR). Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company hasMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.32
Change (%) Stock is Down 0.19 (4.21%)
Volume5,717,157
Oct 22, 2014 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
10/20/14Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese AdultsPrinter Friendly Version
10/15/14Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial LaunchPrinter Friendly Version
09/16/14Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare ConferencePrinter Friendly Version
09/11/14Takeda and Orexigen Announce FDA Approval of Contrave® (naltrexone HCI and bupropion HCI) Extended-release Tablets for Chronic Weight Management Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.